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Progress of Photodynamic Therapy in Gastric Cancer
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Department of Gastroenterology, Osaka Medical Center for Cancer and Cardiovascular Diseases,
1-3-3, Nakamichi, Higashinari-ku, Osaka 537-8511, Japan
Progress of photodynamic therapy (PDT) in gastric cancer and the clinical outcome are
described in this paper. (1) We included the whole lesion and a 5mm margin in the field for
irradiation. Marking by injection of India-ink showing the irradiation field was performed
beforehand. (2) We established the standard light dose to be 90 J/cm
2 for an argon dye
laser and 60 J/cm
2 for a pulse wave laser. (3) The size of cancerous lesion curable by PDT
was expanded from 3cm in diameter, i.e. 7cm in area to 4cm in diameter, i.e. 13cm by
employing a new excimer dye laser model, which could emit 4mJ/pulse with 80Hz pulse
frequency. (4)The depth ofcancer invasion which could be treatedbyPDT was increasedfrom
about 4mm, i.e. the superficial part of the submucosal layer (SM-1) to more than 10mm in
depth, i.e. the proper muscular layer. These improvements owe much to the pulse laser, the
photodynamic action induced by which permits deeper penetration than that of a continuous
wave laser. (5)We employed a side-viewing fiberscope for gastricPDT to irradiate the lesion
from an angle of90. (6)We designed a simple cut quartz fiber for photoradiation with a spiral
spring thickened toward the end. (7)We developed an endoscopic device for photoradiation in
PDT which achieves accurate and efficient irradiation. As a result of these improvements a
higher cure rate was obtained even with a lower light dose of irradiation.
Keywords: Endoscopic treatment, Gastric cancer, Hematoporphyrin derivative (HpD),
Photodynamic therapy, Pulse laser
INTRODUCTION
Since the report on clinicalPDT by Dougherty et al.
[1], and the development of endoscopic PDT for
lung cancer by Hayata et al. [2], we have studiedhow
to apply this method for gastric cancer since 1979.
However, several improvements of techniques and
instruments were required to enable PDT for gas-
tric cancer. In Japan, when early gastric cancer is
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detected, an endoscopicmucosal resection (EMR) is
first considered, because the method is simple to
carry out and pathologic evaluation of the resected
specimen allows assessment of the curativity. Since
small mucosal adenocarcinomas without ulceration
can be cured with less difficulty by EMR, PDT is
indicated in adenocarcinomas with submucosal
invasion and/or ulceration. Gastric cancer lesions
with ulceration usually show infiltrative growth,176 S. MIMURA et al.
thus the boundary between the cancerous lesion and
surrounding mucosa is frequently unclear. More-
over, the edema of the gastric mucosa induced by
laser irradiation further obscures the border. Never-
theless it is essential to overcome these difficulties
for localized gastric PDT. PDT is also indicated to
patients who would be at high risk if treated by
open surgery, e.g. elderly patients and patients with
severe organ dysfunction, because it is impossible to
cure lymph node metastasis by PDT, and it is also
impossible to rule out lymph node micro-metastasis
before treatment. In this paper we describe our
original ideas and how to put them into practice, in
addition to the results in PDT for gastric cancer.
MATERIALS AND METHODS
Materials
We performed PDT in 80 patients (84 lesions) with
early gastric cancer who were poor risks for
conventional surgery. From 1981 to 1990, we
treated 38 cases (41 lesions) by PDT with hemato-
porphyrin derivative [3] (HpD, Photofrin I) or
dihematoporphyrin ether/ester (DHE, Photofrin
II) and an argon dye laser (ADL: models 171-08
and 375-03, Spectra-Physics, Mountain View, CA,
USA). In 1988, we tried a copper vapor dye laser
(CuVDL, models HN 102 and HO 102, Niic,
Kawasaki, Japan) in PDT. However, since we could
not find any advantages of the CuVDL in clinical
use in early gastric cancer, 3 cases treated byCuVDL
were, therefore, included in the ADL group. From
1990 to 1998, we treated 42 cases (43 lesions) byPDT
withpolyhematoporphyrinether/ester(PHE, freeze-
dried Photofrin II, Photofrin (R) Injection and a
pulse laser. The pulse lasers we used were mainly an
excimer dye laser [4] (EDL: model EDL PDT-1,
Hamamatsu Photonics, Hamamatsu, Japan) and
partially between 1995 and 1996 an optical para-
metric oscillator system pumped by a Q-switched
Nd:YAG laser [5] (YOL: model iLS-TL-50A,
Ishikawajima-Harima Heavy Industries (IHI),
Tokyo, Japan). The characteristics of 80 patients
TABLE Patient characteristics
Characteristics Total ADL Pulse laser
(EDLa, YOLb)
Sex
Male 63 26 37
Female 17 12 5
Age
50-59 (years) 9 4 5
60-69 20 10 10
70-79 36 21 15
80-89 14 3 11
90- 0
Tumor location
Upper third 24 17 7
Middle third 29 6 23
Lower third 31 18 13
Histology
tub 45 22 23
tub 2
d 30 15 15
por 2 0 2
sig 7 4 3
Tumor area
1.0 (cm2) 17 10 7
1.1-2.0 8 6 2
2.1-4.0 30 13 17
4.1-7.0 21 8 13
7.1-12.0 6 3 3
12.1- 2
Depth of invasion
Mucosal 41 22 19
Submucosal 43 19 24
Gross type
Elevated 13 8 5
Depressed UI(-)
h 31 18 13
Depressed UI(+) 40 15 25
aEDL: excimer dye laser, byOL: optical parametric oscillator
system pumped by a Q-switched Nd:YAG laser. Ctub 1: well-
differentiated tubular adenocarcinoma, dtub 2: moderately
differentiated tubular adenocarcinoma, epor: poorly differen-
tiated adenocarcinoma, fsig: signet-ring cell carcinoma.
h Elevated: superficial elevated type. Without ulceration, iWith
ulceration.
(84 lesions) are shown in Table I. The characteris-
tics of lasers we have used for PDT are shown in
Table II.
Method
The PDT procedure includes three important
points, i.e. administration of photosensitizers, laser
light irradiation, and pre- and post-procedural
management (Table III).PROGRESS OF PDT IN GASTRIC CANCER 177
TABLE II Laser characteristics
Model of Pulse energy Peak power Pulse width Pulse frequency Average output Light dose-rates in
laser (mJ) (ns) (Hz) (mw) gs (J)
ADL (300mW) 300 3 10
-7
CuVDL 0.055 2.5kW 22 5,500 300 5.5 10
-5
EDL, ordinary 4 400kW 10 40 160 4 10
.3
EDL, new model 4 400kW 10 80 320 4 10
-3
YOL 5 700kW- MW 5-8 50 250 5 x 10
.3
ADL: argon dye laser. CuVDL: copper vapor dye laser. EDL: excimer dye laser. YOL: optical parametric oscillator systempumped by a
Q-switched Nd YAG laser.
TABLE III PDT procedure
1. Intravenous injection of 3 mg/kg ofHpD or 2mg/kg ofDHE
or PHE.
2. Approximately 50 h later, the entire lesion plus a 5mm
margin ofmucosa is irradiated with a laser beam. Standard
doses: 90 J/cm with ADL, 60 J/cm with EDL or YOL.
3. Patients are protected from hypersensitivity to light, and are
treated for post-treatment ulcer.
Administration of Photosensitizer
Three mg/kg of HpD or 2 mg/kg ofDHE or PHE
was given intravenously. The Ministry of Health
and Welfare of Japan approved PDT [6] in 1994,
and Photofrin Injection(R) became commercially
available in 1995.
Laser Light Irradiation
Approximately 50 h after intravenous injection of
photosensitizer, the entire lesion plus a 5mm wider
perimeter of mucosa was irradiated with a laser
beam at 630nm wavelength transmitted endosco-
pically. The laser beam was condensed and trans-
mitted through a 400-gm core diameter quartz fiber
via the working channel. For extensive lesions, the
irradiation field was first set on the distal portion of
the lesion, and after delivering the scheduled dose of
light there, the field of irradiation was shifted to the
remaining part to irradiate the entire region as
uniformly as possible. Assuming that the irradiation
was uniform, the total energy intensity (J/cm2) was
calculated by the following formula:
total energy intensity (J/cm2)
average output (W) x time (s)
/total irradiated area (cm2)
(in a continuous wave laser),
or
pulse energy (J/pulse)
x pulse frequency (pulse/s)
x time (s)/total irradiated area (cm2)
(in a pulse laser).
Side-viewing fiberscope In gastric PDT we
usually used a side-viewing gastro-fiberscope
(model GF type B3, OES GF 10 and 20, Olympus,
Tokyo, Japan) to observe the lesion from an angle
of 90, keeping a certain distance between the fiber
tip for irradiation and the lesion. In this way
accurate photoradiation is possible throughout the
stomach.
New fiber for photoradiation When using the
side-viewing fiberscope, we need to bend the
quartz fiber 90 with a curvature radius of 20mm.
Although the 400-gm core diameter quartz fiber
did not mechanically break, when bent in such a
fashion it would form an "elbow", and the laser
beam would ooze from the core at the elbow and
overheat. Currently, we therefore developed a new
fiber with a spiral spring [7] (Hamamatsu Photo-
nics, Hamamatsu, Japan). The spring, which was
made of a stainless steel wire 100 lam in diameter,
was made 6mm in length, thickened toward the178 S. MIMURA et al.
end. It was fixed at the fiber tip and encased in a
1.5mm outer diameter Teflon tube. It did not
disturb passage of air but protected the fiber from
destruction, because it ensured an even curvature
and prevented the formation of an "elbow". This
fiber is low-cost, can withstand bending and more-
over is easy to repair.
A new device for PDT In gastric PDT there
was the problem of the dazzling reflection of the
red laser light during photoradiation. Initially we
placed a green filter (models SP-15 and SP-19, Fuji
Filter, Tokyo, Japan) on the eyepiece of the fiber-
scope and in front of the charge coupled device
(CCD) of an old OES-TV system (model OTV-F2,
Olympus). The red spot of laser light could be
observed clearly, but the mucosal image turned to
green and dark, and the boundary of the cancerous
lesion became unclear. Recently, we therefore
developed a new device [8] for photoradiation
which consisted of a conventional fiberscope and a
new OES-TV system (model OTV-S5, Olympus).
In front of the CCD we inserted a new interference
filter which had specific absorption of red light
with a 2.3% transmissivity at 630nm wavelength
and a 50nm absorption band of full width at half
maximum, while the average transmittance in the
visible region was 90% (Hamamatsu Photonics).
In this way we could observe the mucosa clearly
during the entire course of irradiation.
Pre- and Post-Procedural Management
Soon after injection of the photosensitizer, the
patients were placed in a dark room. After PDT,
the patients were kept in bed without oral feeding
and were given continuous intravenous glucose and
saline with an H2-blocker and antibiotics for two
days to allow healing of ulcers. During this period,
the patients were kept in dim light and their faces and
hands were coated with antisunburn cream. These
restrictions were gradually reduced, and the patients
returned to normal conditions after one week.
Evaluation of Response
The response was evaluated by endoscopy with
biopsy and cytology in follow-up examinations.
They were followed up by endoscopy 2, 3 and 6
months later, then every 6 months for 2 years, and
thereafter once a year. To detect metastasis to the
lungs, liver, and abdominal lymph nodes, the
patients were also followed up by chest X-ray and
ultrasonic echography. Curativity was divided into
two categories: ’cure’ or ’no cure’. Although it is
impossible to prove that cancer was completely
cured based on clinical examinations, our definition
of ’cure’ was when neither local recurrence nor
metastasis were detected by follow-up examinations
at year. Cases classified as partial response and
recurrence after year, therefore, were classified as
’no cure’ in our evaluation [9].
RESULTS
Patient Characteristics
Patient characteristics and response in relation to
the kind of laser used are summarized in Table IV.
The effects of PDT with the ADL in early gastric
cancer lesions, according to the depth of cancer
invasion are shown in Table V. The rate of cure for
mucosal carcinomas was 59% (13/22), that of
submucosal carcinomas was 53% (10/19) and the
overall rate was 56% (23/41). The effects of PDT
with the pulse laser, that is EDL or YOL, according
to the depth of cancer invasion are shown in
Table VI. The pulse laser improved cure rates
markedly to 95%, i.e. 18 of 19 mucosal cancers,
and 75%, i.e. 18 of 24 in submucosal cancers, and
84%, i.e. 36 of 43 overall.
Among them the most extensive lesions cured
by PDT were 19 and 12 cm
2 lesions of the mucosal
and submucosal carcinoma, respectively. Cure was
obtained in a 79-year-old man with a lesion
spreading 19 cm
2 in the mucosal layer. The super-
ficial elevated type lesion was located in the middle
third of the stomach on the lesser curvature, and
biopsy revealed well-differentiated tubular adeno-
carcinoma. Photoradiation with the YOL through
a quartz fiber with a concave lens (Ishikawajima-
Harima Heavy Industries) was performed at 53 h
after administration of PHE, giving 1,080 J overPROGRESS OF PDT IN GASTRIC CANCER 179
TABLE IV Response in relation to treatment with ADL or pulse laser
Kind of laser Argon dye laser
Characteristics Total
Pulse laser (EDLa, YOLb)
CR Non-CR Total CR Non-CR
Sex
Male 26 12 14 37 31 6
Female 12 8 4 5 4
Age
50-59 (years) 4 2 2 5 5 0
60-69 10 3 7 10 7 3
70-79 21 14 7 15 14
80-89 3 2 11 8 3
90- 0 0 0 0
Tumor location
Upper third 17 11 6 7 7 0
Middle third 6 3 3 23 18 5
Lower third 18 9 9 13 11 2
Histology
tub ld 22 11 11 23 21 2
tub 2 15 10 5 15 12 3
por 0 0 0 2 2 0
sig 4 2 2 3 2
Tumor area
1.0 (cm2) 10 7 3 7 7 0
1.1-2.0 6 5 2 2 0
2.1-4.0 13 8 5 17 12 5
4.1-7.0 8 2 6 13 11 2
7.1-12.0 3 2 3 3 0
12.1- 0 0
Depth of invasion
Mucosal 22 13 9 19 18
Submucosal 19 10 9 24 18 6
Gross type
Elevated
h 8 4 4 5 4
Depressed UI(-) 18 10 8 13 12
Depressed UI(+) 15 9 6 25 20 5
b EDL: excimer dye laser. YOL: optical parametric oscillator system pumped by a Q-switchedNd YAG laser. CR: complete response.
dtub 1: well-differentiated tubular adenocarcinoma, tub 2: moderately differentiated tubular adenocarcinoma, por: poorly
differentiated adenocarcinoma, gsig: signet-ring cell carcinoma, hElevated: superficial elevated type. iWithout ulceration. JWith
ulceration.
TABLE V Rates of cure of early gastric cancer obtained by
PDT with an ADL according to depth
Depth of invasion Number of Number of
lesions CR lesions (%)
Mucosa 22 13 (59%)
Submucosa 19 10 (53%)
Total 41 23 (56%)
aADL: argon dye laser.
TABLE VI Rates of cure of early gastric cancer obtained by
PDT with pulse laser (EDLa, YOLb) according to depth
Depth of invasion Number of Number of
lesions CR lesions (%)
Mucosa 19 18 (95)
Submucosa 24 18 (75)
Total 43 36 (84)
aEDL: excimer dye laser, byOL: optical parametric oscillator
system pumped by a Q-switched Nd:YAG laser.180 S. MIMURA et al.
27cm2, which was calculated as 40J/cm
2 total
energy intensity.
Cure was also achieved by PDT in a 64-year-old
man with an extensive early gastric cancer lesion
with submucosal invasion. The lesion was the
superficial depressed type with ulceration, located
in the middle third of the stomach on the lesser
curvature, spreading over 12cm2. Biopsy revealed
signet-ring cell carcinoma and the depth ofinvasion
suggested by endoscopic ultrasonography was the
full depth of the submucosal layer (SM-3) border-
ing on the proper muscular layer. PDT was carried
out with an EDL using a simple cutting quartz fiber
without lens or diffuser, giving 48 J/cm
2 to a 15 cm
2
area [10].
During the same periods, we treated 8 patients
with advanced gastric cancer by PDT, 2 with an
ADL and 6 with an EDL and one of the latter
achieved a complete cure, that is complete remission
without recurrence at year.
DISCUSSION
The Irradiation Field
It was our original intention to include a normal
mucosal margin of 5mm width for irradiation, and
this was carried out, with only few exceptions, since
the first treated case. For extensive lesions, the
irradiation field was first set on the distal portion of
the lesion, and after delivering the scheduled dose of
light there, the field of irradiation was shifted to the
remaining part. We began at the distal portion
because the edema of the mucosa induced by irra-
diation will conveniently raise the lesion toward a
proximal direction, and also because photoradia-
tion can cause the gastric wall to become spastic
and would push out the fiberscope gradually, there-
fore it would become difficult to insert the fiber-
scope into the distal portion in the later period of
the treatment.
Side Effects
In one case treated with the EDL, massive bleeding
occurred from an ulcer produced after PDT. The
hemoglobin decreased to 6.2g/dl, but recovered
following conservative treatment such as blood
transfusion, so endoscopic hemostasis did not have
to be carried out. In four other cases, mild cutaneous
reaction and photosensitivity lasted several weeks.
In one other case, mild cutaneous pigmentation
lasted several months. The main abnormality
revealed by laboratory tests was decrease of total
protein, which was observed in 32 patients (40%)
and was thought to be caused by protein loss from
the base of the ulcer that developed after PDT and
acute gastritis surrounding the ulcer. Fourteen
patients out of 32 recovered within several months
with a normal diet, while 18 patients, with a ten-
dency toward hypoalbuminemia before treatment,
such as in liver cirrhosis, required intravenous
injections of 150-1100 ml of 25% human albumin.
Slight liver dysfunction was seen in 5 patients,
lasting for several weeks. No serious adverse
reactions were seen.
Energy Intensity
The appropriate energy intensity level is also
important. Kato et al. [11] endoscopically delivered
more than 200J/cm
2 by an ADL and more than
100 J/cm
2 by an EDL for lung cancer. Udagawa [5]
reported the results of clinical trials of PDT in
several organs using a YOL, in which he reported
100-300 J/cm
2 for early lung cancer and CIS of the
uterine cervix, and 60-180 J/cm
2 for early gastric
cancer and superficial esophageal cancer. We gave
204 J/cm
2 for our first case of superficial esophageal
cancer and 90 J/cm
2 for our first case ofearly gastric
cancer. After trials using several doses, we recog-
nized that the tumor response did not correspond to
the light dose, while homogeneous irradiation
including a sufficient margin was essential. There-
after, we established the standard light dose to be
90 J/cm
2 for theADL and 60 J/cm
2 for the EDL and
YOL for superficial esophageal cancer and early
gastric cancer. There has been much discussion why
smaller doses with the pulse laser are enough. In
spite of no clinical randomized comparative trials
between a continuous wave laser and a pulse laser,
it was proved that 60 J/cm
2 of the EDL or YOLPROGRESS OF PDT IN GASTRIC CANCER 181
was enough to obtain a complete response (CR)
for superficial esophageal cancer and early gastric
cancer 12-15].
PDT for Extensive Lesions
Although the size of the lesion which can be treated
by PDT is limited by the duration of treatment time
tolerated by the patients, i.e. within approximately
h in our experience, even if a patient can bear an
additional irradiation session, the lesion and the
surrounding mucosa will have become edematous
with partially hemorragic necrosis, and moreover
the surface will be covered with a white, partially
black membrane which consists of a coagulated
mixture of mucus, serum protein exudate and
blood. It is difficult to remove the membrane with-
out causing bleeding. The maximum size of a lesion
that can be treated by PDT is the maximum area
including the whole lesion plus a 5mm margin
to which the laser can give the standard dose of
60 J/cm
2 in h. This depends on the average output
of the laser. In the new EDL model as shown in
Table II, the pulse frequency can be increased to
80 Hz, yielding an average output of 320mW. By
shortening the irradiation time for a certain
energy, i.e. 60 J, the application of PDT can be
extended to larger lesions up to 4cm in diameter
(13 cm2) giving treatment for h [16]. In practice,
extensive lesions spreading over 19cm2 in the
mucosa and 12cm
2 in the submucosa were cured
by irradiation with only 40 and 48 J/cm2, respec-
tively as described above. These results suggest
thatPDT can be indicated for more extensive lesion
with less energy intensity.
Depth of Cancer Invasion
The depth ofphotodynamic action depends on three
factors: the transmissivity of the tissue, the density
and sensitivity of photosensitizer, and the laser
characteristics including its wavelength. Does the
depth of photodynamic action also depend on the
laser characteristics apart from its wavelength?
In spite of using the same energy intensity, it was
demonstrated not only in animal tumors [17] but
also in clinical cases [18] that a pulse laser with an
extremely high peak power had more efficient
photodynamic action than a continuous wave laser
such as anADL or a high frequency pulse laser such
as a CuVDL. However, the theory proving why a
pulse laser could be superior to a continuous wave
laser was not developed until 1994, when Takemura
et al. [19] proved it by introducing the concept of
light dose-rate effects. He proposed that if there are
thresholds of.dose-rates of laser light to activate the
photosensitizer, the depth would vary according to
the light dose-rates. The hypothesis of thresholds of
light dose-rates was subsequently recognized. In
normal PDT the intensity of the laser light on the
surface of the lesion is enough to activate the
photosensitizer, whereas the deeper the light pene-
trates the tissue the weaker it would become.
Finally, the intensity of the light would weaken to
the threshold of the light dose-rates. This point cor-
responds to the maximum depth of photodynamic
action. As the light dose-rates, i.e. the energy inten-
sity for s, depends on the average output, it might
appear that there would be no difference between
a continuous wave laser and a pulse laser. How-
ever, it is necessary to give strict consideration to
the consumption time period for activation of the
photosensitizer and production of singlet oxygen,
which is approximately s(10-6). Therefore, if
energy greater than the threshold can be given in ts
or less will decide the effect of the photodynamic
action. The energy intensity in ts of an ADL of
300mW irradiated to an area of cm2 is 3 10-7 J,
whereas that of an EDL or YOL is 4 10
-3 and
5 10
-3 J, respectively, that is more than 10,000
times that of the ADL. The light dose-rates for ts
for each laser are shown in Table II. Although it is
not yet recognized internationally that the energy
intensity for ts is the most important factor to
decide the depth of effective photodynamic action,
the therapeutic effects on gastric cancer more than
10mm in depth supports this hypothesis.
In 1993, we eventually succeeded in treating an
80-year-old man with advanced gastric cancer by182 S. MIMURA et al.
PDT [20]. This lesion was advanced gastric cancer
type 2, localized depressed type, located in the
middle third of stomach and its area was 13 cm2.
Biopsy revealed a moderately differentiated tubular
adenocarcinoma (tub 2), and the depth of invasion
suggested by endoscopic ultrasonography was PM,
i.e. the cancer invaded the proper muscular layer,
revealing 10mm in tumor thickness. PDT was
performed withPHE and a newEDL using a quartz
fiber with a concave lens, delivering 48 J/cm
2 to an
area of 15 cm2, and complete cure was obtained.
Follow up for year after PDT demonstrated no
local recurrence ofcancer and absence ofmetastasis
was indicated by chest X-ray, ultrasonic echography
and computed tomography.
CONCLUSION
Through improvements of techniques and instru-
ments a high rate of cure can be obtained in
submucosal gastric cancer including lesions with
ulceration by PDT with PHE and a pulse laser. The
new EDL model which can emit 80Hz pulse
frequency allows more extensive lesions to be
treated. Finally, a complete remission without
recurrence was achieved by PDT in one case of
advanced gastric cancer.
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